Tekmira Pharmaceuticals this week announced the release of preclinical data showing that its lipid nanoparticles can be used to deliver messenger RNA into the liver, tumors, and other tissues in vivo.
The data were presented at the International mRNA Health conference in Germany this week.
"Because [lipid nanoparticles] can enable a wide variety of nucleic acid payloads, including messenger RNA, we continue to see new product development and partnering opportunities based on our … delivery expertise," Tekmira President and CEO Mark Murray said in a statement.